MA42361A1 - Composition pharmaceutique contenant, en tant que principe actif, un dérivé ou un sel pharmaceutiquement acceptable de 7-azaindolin-2-one - Google Patents

Composition pharmaceutique contenant, en tant que principe actif, un dérivé ou un sel pharmaceutiquement acceptable de 7-azaindolin-2-one

Info

Publication number
MA42361A1
MA42361A1 MA42361A MA42361A MA42361A1 MA 42361 A1 MA42361 A1 MA 42361A1 MA 42361 A MA42361 A MA 42361A MA 42361 A MA42361 A MA 42361A MA 42361 A1 MA42361 A1 MA 42361A1
Authority
MA
Morocco
Prior art keywords
azaindolin
pharmaceutically acceptable
salt
pharmaceutical composition
active ingredient
Prior art date
Application number
MA42361A
Other languages
English (en)
Inventor
Byeong-Seon Jeong
Jung-Ae Kim
Tae-Gyu Nam
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of MA42361A1 publication Critical patent/MA42361A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne un dérivé ou un sel pharmaceutiquement acceptable de 7 azaindolin-2-one. Ledit dérivé ou sel pharmaceutiquement acceptable de 7-azaindolin-2-one peut être utilisé avantageusement comme substance médicinale pour inhiber la croissance du cancer et de métastases cancéreuses.
MA42361A 2015-11-12 2016-10-31 Composition pharmaceutique contenant, en tant que principe actif, un dérivé ou un sel pharmaceutiquement acceptable de 7-azaindolin-2-one MA42361A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20150158695 2015-11-12
PCT/KR2016/012409 WO2017082569A1 (fr) 2015-11-12 2016-10-31 Composition pharmaceutique contenant, en tant que principe actif, un dérivé ou un sel pharmaceutiquement acceptable de 7-azaindolin-2-one

Publications (1)

Publication Number Publication Date
MA42361A1 true MA42361A1 (fr) 2018-09-28

Family

ID=58695675

Family Applications (1)

Application Number Title Priority Date Filing Date
MA42361A MA42361A1 (fr) 2015-11-12 2016-10-31 Composition pharmaceutique contenant, en tant que principe actif, un dérivé ou un sel pharmaceutiquement acceptable de 7-azaindolin-2-one

Country Status (18)

Country Link
US (1) US10544140B2 (fr)
EP (1) EP3363799A4 (fr)
JP (1) JP6661766B2 (fr)
KR (1) KR102109869B1 (fr)
CN (1) CN108368108B (fr)
AU (1) AU2016353573B2 (fr)
BR (1) BR112018009482A2 (fr)
CA (1) CA3004595A1 (fr)
CL (1) CL2018001236A1 (fr)
CO (1) CO2018005367A2 (fr)
EA (1) EA201891136A1 (fr)
IL (1) IL259083A (fr)
MA (1) MA42361A1 (fr)
MX (1) MX2018005894A (fr)
NZ (1) NZ742228A (fr)
PH (1) PH12018500946A1 (fr)
WO (1) WO2017082569A1 (fr)
ZA (1) ZA201803722B (fr)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9721437D0 (en) * 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
CA2383623A1 (fr) * 1998-08-04 2000-02-17 Sugen, Inc. Modulateurs 3-methylidenyl-2-indolinone de proteine kinase
CO5271715A1 (es) * 1999-12-21 2003-04-30 Sugen Inc 7-aza-indolin-2-onas sustituidas en 4 y su uso como inhibidores de proteiuna quinasa
RU2468022C2 (ru) * 2008-05-23 2012-11-27 Шанхай Инститьют Оф Фармасьютикал Индастри Производные дигидроиндолона
US9040555B2 (en) * 2012-01-26 2015-05-26 Angion Biomedica Corp. Antifibrotic compounds and uses thereof
CN104884059B (zh) 2012-11-30 2018-08-10 罗切斯特大学 用于hiv/aids治疗的混合谱系激酶抑制剂
US9187454B2 (en) * 2013-03-13 2015-11-17 Boston Biomedical, Inc. Inhibitors of kinases and cancer stem cells, and methods of preparation and use thereof
US20160031888A1 (en) * 2013-03-13 2016-02-04 Boston Biomedical, Inc. 3-(aryl or heteroaryl) methyleneindolin-2-one derivatives as inhibitors of cancer stem cell pathway kinases for the treatment of cancer
CN104876928B (zh) * 2015-05-07 2016-09-14 浙江司太立制药股份有限公司 7-氮杂吲哚啉-2-酮类化合物及其制备方法

Also Published As

Publication number Publication date
KR20170056430A (ko) 2017-05-23
JP6661766B2 (ja) 2020-03-11
PH12018500946A1 (en) 2018-11-12
IL259083A (en) 2018-06-28
EP3363799A4 (fr) 2018-12-05
MX2018005894A (es) 2018-08-15
CO2018005367A2 (es) 2018-06-12
WO2017082569A1 (fr) 2017-05-18
ZA201803722B (en) 2019-03-27
KR102109869B1 (ko) 2020-05-13
BR112018009482A2 (pt) 2018-11-06
CL2018001236A1 (es) 2018-08-24
AU2016353573B2 (en) 2019-11-21
US20180370964A1 (en) 2018-12-27
CN108368108B (zh) 2021-09-21
EP3363799A1 (fr) 2018-08-22
CN108368108A (zh) 2018-08-03
NZ742228A (en) 2019-09-27
CA3004595A1 (fr) 2017-05-18
JP2018533600A (ja) 2018-11-15
US10544140B2 (en) 2020-01-28
EA201891136A1 (ru) 2018-10-31
AU2016353573A1 (en) 2018-05-24

Similar Documents

Publication Publication Date Title
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
NZ780890A (en) Pharmaceutical compositions comprising meloxicam
MX2019013954A (es) Inhibidores covalentes de kras.
MX383856B (es) Compuestos y composiciones para inhibir la actividad de shp2.
MX387604B (es) Formulaciones cannabinoides estables.
MX379155B (es) Compuestos que inhiben la proteína mcl-1.
EA201691242A1 (ru) Фармацевтические композиции, содержащие azd9291
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA202190960A1 (ru) Конденсированные пирролины, которые действуют как ингибиторы убиквитин-специфической протеазы 30 (usp30)
JOP20180071B1 (ar) استخدام مشتقات أمينو ألكيل بنزوثيازبين
EA201791259A1 (ru) Производные пиперидина в качестве ингибиторов hdac1/2
EP4553065A3 (fr) Nouveaux composés pour le traitement d'une maladie mitochondriale
EP3417853A4 (fr) Composition pharmaceutique pour le traitement d'un cancer, contenant un composé polyphénol utilisé comme principe actif
MA39443A1 (fr) Nouvelle formulation de méloxicam
EA202190588A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
SA521422152B1 (ar) Vanin مركبات عطرية غير متجانسة كمثبطات
EA201591649A1 (ru) Составы с органическими соединениями
EP3480186A4 (fr) Nouveau dérivé d'aryléthane et composition pharmaceutique contenant ce dérivé comme principe actif
EA202191478A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
MA43876B1 (fr) Compositions pharmaceutiques et leur utilisations contre les maladies de surcharge lysosomale
EA201890906A1 (ru) ПРОИЗВОДНЫЕ ХИНОКСАЛИНА И ПИРИДОПИРАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ
IL281353A (en) Pharmaceutical composition for preventing or treating nonalcoholic fatty liver disease, containing gpr119 ligand as active ingredient
ZA201904591B (en) Dexmedetomidine or medetomidine for use in treating separation anxiety in dogs
EP3404020A4 (fr) Dérivé de pyridinol ou sel pharmaceutiquement acceptable de celui-ci, et composition pharmaceutique contenant celui-ci utilisé comme principe actif
EA201990550A1 (ru) Офтальмологический препарат, включающий азоловое соединение